Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival

Clinical Colorectal Cancer

Volumn 4, Issue 4, 2004, Pages 262-267

  Ochs, Ann Margaret ^a,d   Wong, Lucas ^a   Kakani, Vijaya ^c   Neerukonda, Srilatha ^b   Gorske, Julie ^a   Rao, Arundhati ^a   Riggs, Mark ^a   Ward, Heather ^a   Keville, Lisa ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Collom Carney Clinic ^*  (United States)

^c Medical and Surgical Specialists LLC   (United States)

^d Temple TX 76508   (United States)

Author keywords

Adenocarcinoma; Angiogenesis; Bevacizumab; Prognostic factors; Trastuzumab; Vasculogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; CORRELATION FUNCTION; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 10944257660     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.025     Document Type: Article

References (38)

1. Tominaga T, Sakabe T, Koyama Y, et al. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Cancer 1996; 78:403.
2. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112:1103-1113.
3. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6:2803-2807.
4. D'Emilia J, Bulovas K, D'Ercole K, et al. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989; 4:1233-1239.
5. Tsioulias GJ, Muto T, Morioka Y, et al. erbB-2 gene expression in colorectal cancer. Jpn J Exp Med 1990; 60:343-349.
6. Tal M, Wetzler M, Josefberg Z, et al. Sporadic amplification of the HER-2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988; 48:1517-1520.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
8. Berger MS, Locher GW, Sauter S, et al. Correlation of c-erb-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48:1238-1243.
9. Wright C, Angus B, Nicholson S, et al. Expression of c-erb-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49:2087-2090.
10. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erb-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8:103-112.
11. Muss HB, Thor AD, Berry DA, et al. C-erb-2 expression and respouse to adjuvant therapy in women with node positive early breast cancer. N Engl J Med 1994; 330:1260-1266.
12. Wright C, Nicholson S, Angus B, et al. Relationship between c-erb-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65:118-121.
13. Hsieh CC, Chow KC, Fahn HJ, et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of the lung. Ann Thorac Surg 1998; 66:1159-1164.
14. Nathanson DR, Culliford AT IV, Shia J, et al. HER-2/neu expression and gene amplification in colon cancer. Int J Cancer 2003; 105:796-802.
15. Arnaout AH, Dawson PM, Soomro S, et al. HER-2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J Clin Pathol 1992; 45:726-727.
16. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
17. Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor performance prognosis in colon cancer. Br J Cancer 1998; 77:998-1002.
18. Takahashi Y, Mai M, Kitadai Y, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968.
19. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78:1379-1384.
20. Nakata S, Ito K, Fujimori M, et al. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 1998; 79:179.
21. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 proto-oncogenes in human adenocarcinoma in vivo. Lancet 1986; 1(8484):765-767.
22. Gutman M, Ravia Y, Assat D, et al. Amplification of c-Myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 1989; 44:802-805.
23. McCann A, Dervan PA, Johnston PA, et al. C-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990; 65:88-92.
24. Natali PG, Nicotra. MR, Bigotti A, et al. Expression of the p185 encoded by HER-2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45:457-461.
25. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554-568.
26. Caruso ML, Valentini AM. Immumohistochemistry, p53 overexpression correlated to c-erbB-2 cathepsin D proteins in colorectal cancer. Anticancer Res 1996; 16:3813-3818.
27. Kay EW, Mulcahy H, Walsh CB, et al. Cytoplasmatic c-erbB-w protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994; 25:455-461.
28. Kraus MH, Popescu NC, Amsbaugh SC, et al. Overexpression of the EGF receptor-related protooncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987; 3:605-610.
29. De Potter CR, Quatacker J, Maertens G, et al. The subcellular localization of the neu protein in human normal and neoplastic, cells. Int J Cancer 1989; 44:969-974.
30. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 1989; 60:426-429.
31. Nichols DW, Wolff DJ, Self S, et al. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci 2002; 32:3-11.
32. Diaz, NM. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control 2001; 8:415-418.
33. McCormick SR, Lillemoe TJ, Beneke J, et al. HER2 assessment by immunohistochemical analysis and FISH: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002; 117:935-943.
34. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541-546.
35. Khorana AA, Ryan CK, Cox C, et al. Vascular endothelial growth factor, CD 68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma. Cancer 2003; 97:960-968.
36. Zheng S, Han MY, Xiao ZX, et al. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. W J Gastroenterol 2003; 9:1227-1230.
37. Nakayama Y, Sako T, Shibao K, et al. Prognostic value of plasma VEGF in patients with colorectal cancer. Anticancer Res 2002; 22:2437-2442.
38. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114:853-865.